<DOC>
	<DOC>NCT02483936</DOC>
	<brief_summary>The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.</brief_summary>
	<brief_title>Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCTÂ® in Essential Hypertension Control</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Chlorthalidone</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Signed Consent of the patient; Participants with decompensated essential hypertension, classified into stage 1 (with high or very high cardiovascular risk), stage 2 or stage 3 according to the Brazilian Society of Cardiology (2010), who are being treated with monotherapy. Patients with any clinically significant disease that in the investigator opinion can not participate in the study; Secondary hypertension diagnosis or blood pressure above 190x100 mmHg in the screening/randomization visit; Morbid obesity or immunocompromised patients; Participants with greater than 10 mmHg difference in the measurements of systolic or diastolic blood pressure between the two arms; Participants who do not have the two upper limbs; Participants with important electrocardiographic changes; Creatinine clearance less than 60 mL / min; History of hypertensive emergencies and cardiovascular and / or moderate to severe cerebrovascular events in the past 6 months; Microalbuminuria urine sample greater than 30 mg/g; Patients with history of hypersensitivity to any of the formula compounds; Pregnancy or risk of pregnancy and lactation patients; Participation in clinical trial in the year prior to this study;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>